Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tenaya Therapeutics ( (TNYA) ) has provided an update.
On December 11, 2025, Tenaya Therapeutics announced the pricing of its public offering of 50 million units, expected to raise approximately $60 million. The proceeds will fund the development of clinical and early-stage product candidates, including TN-201 and TN-401, and support general corporate purposes. The offering is set to close on December 15, 2025, subject to customary conditions.
The most recent analyst rating on (TNYA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Tenaya Therapeutics stock, see the TNYA Stock Forecast page.
Spark’s Take on TNYA Stock
According to Spark, TipRanks’ AI Analyst, TNYA is a Underperform.
Tenaya Therapeutics’ overall score is primarily impacted by its financial performance, characterized by pre-revenue status and high cash burn due to R&D expenses. Technical indicators highlight a bearish trend, with the stock trading below key moving averages and near oversold conditions. Valuation metrics reflect non-profitability and lack of dividend yield, typical for early-stage biotech firms.
To see Spark’s full report on TNYA stock, click here.
More about Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease. Their pipeline includes gene therapies for hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, as well as a small molecule inhibitor for heart failure.
Average Trading Volume: 3,511,109
Technical Sentiment Signal: Hold
Current Market Cap: $233.1M
See more insights into TNYA stock on TipRanks’ Stock Analysis page.